// App-Quantinova.ai

: DNA mismatch repair deficiency and outcomes of patients with resectable locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery and postoperative S-1: A sub-analysis of the phase 3 PRODIGY trial.

Researchers

Presenter

  • Jaewon Hyung

Principal Investigators

  • Young Soo Park

  • Hyungwoo Cho

  • Hyung-Don Kim

  • Min-Hee Ryu

  • Yoon-Koo Kang

Medical Centers

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

Locations

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Mismatch repair deficiency

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 206

  • DNA mismatch repair status

Drug/Treatment

  • Oxaliplatin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved